



Emicizumab for Hemophilia A: Effectiveness and Value

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its upcoming report on emicizumab for Hemophilia A. ICER will invite input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER often receives comments from individual patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories.

For a complete list of key dates and opportunities for input on this project, please visit ICER's website.

- American Society of Hematology
- American Thrombosis and Hemostasis Network (ATHN) Registry
- CVS Caremark
- Express Scripts
- Genentech
- Hemophilia Alliance
- Hemophilia Federation of America
- National Hemophilia Foundation
- New England Hemophilia Association
- New England State Consortium Systems Organization (New England Medicaid Programs)
- Novo Nordisk
- Roche
- Shire
- United Hemophilia Foundation
- World Federation of Hemophilia